EUCTR2016-003046-87-AT进行中（未招募）1 期
A multicenter, open Label study to assess the safety and efficacy of rIsankizuMab for MaInTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects with moderate to severe chronic plaque psoriasis who have completed one of the preceding studies 1311.3, 1311.4, 1311.13, 1311.28, 1311.30, 1311.38 and M16-178.
- •2. Subjects must be candidates for prolonged open label risankizumab treatment according to investigator judgment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1800
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 400
排除标准
- •1. Premature discontinuation for any reason in the preceding study.
研究者
相似试验
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisPsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-003046-87-PLAbbVie Deutschland GmbH & Co. KG2,200
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisEUCTR2016-003046-87-PTAbbVie Deutschland GmbH & Co. KG2,200
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisEUCTR2016-003046-87-FRAbbVie Deutschland GmbH & Co. KG2,000
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisPsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-003046-87-SEAbbVie Deutschland GmbH & Co. KG2,200
进行中（未招募）
1 期
A multicenter, open label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasisPsoriasisMedDRA version: 19.1Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2016-003046-87-ESAbbVie Deutschland GmbH & Co. KG1,900